Subject index of Volume 136 · 1998

ABT-089 50
ABT-418 50
Activity 105
Acute tolerance 91
Adenosine A_1 receptor 311
Adenylyl cyclase 34
Adrenalectomy 24
Adrenocorticotropic hormone (ACTH) 342
Affinity 15
Alcohol 1, 91
Alcohol sensitivity 91
Aldosterone 342
Alternate-day dosing 217
Alzheimer's disease 256
1-(2,5-Dimethoxy-4-methylphenyl)2-amino-propane (DOM) 409
Amnesia 328
AMPA 123
Amphetamine 75
Anabaseine 320
Anticholinesterase agent 256
Antidepressant 114, 190
Antidepressant-associated mania 243
Antinociception 15
Antipsychotic 123
Anxiety 148, 291, 311, 402
Anxiety disorder 243
Anxiolytic drug 99
AP5 105
Arousal 75, 235, 247
Atypical antipsychotic drug (neuroleptic) 367
Auditory evoked response 320
Aversion 247
Baclofen 328
Behavior 123, 162, 190
Behavior therapy 205
Behavioral sensitization 34
Behavioural switching 235
Binge 402
Brain activation 179
Brain blood flow 335
Buprenorphine 15, 217
Buspirone 357
Butorphanol 59
C57BL/6 mice 44
Caffeine 264
Calcium channel antagonist 335
Catecholamines 75
Cercopithecus aethiops 1
Cerebrospinal fluid 1
Cholinergic neurotransmission 256
Cholinergic system 349
Chronic mild stress 272
Cigarette smoking 172
Climbing 123
Clocinnamox 15
Clomipramine 114
Clozapine 153, 367
Cocaine 24, 70, 139, 247, 335, 402
Cocaine discrimination 44
Cognition 50, 179
Cognitive enhancer 349
Conditioned place preference 105
Contingency 83
Convulsion 162
Correlation dimension 264
Corticosterone 24
Corticotropin-releasing factor 247
Cortisol 342
CP-93,129 304
Craving 272
D_3 antagonist 284
D_3 dopamine receptor 284
DA and NE release 153
d-Amphetamine 114
Delay matching 50
Depression 198, 272
Deramciclane 99
Desipramine 190, 299
Dextrose 201
d-Fenfluramine 198
Diazepam 114
Diphenhydramine 328
Distractibility 50
Dopamine 1, 24, 59, 75, 105, 123, 190
Dopamine D_2 receptor 367
Dopamine transporter 44, 139
Dose 83
Dose-response relationship 264
Drug dependence 308
Drug discrimination 59, 379
DSP4 235
DSP-4 299
Duloxetine 190
EEG 264
Efficacy 15
EGb 761 148
Ethanol 379
Ethological assessment 284
Etonitazene 15
Etorphine 15
Ex-vivo binding 311
Fear 162
Feeding 83, 304
Fluoxetine 44, 190
Food 70
Forced swimming 190
Forced swimming test 226
GABA 132
General anxiety disorder (GAD) 357
Genetic selection 91
Ginkgolic acid conjugates 148
Glucose 349
Glutamate 123
GPA 1657 15
GR 103691 284
GTS-21 320
Guanfacine 8
Hallucinogenic drug 409
Haloperidol 153, 367
Heart rate variability 390
Heroin 217
Hippocampus 320
5-HT_{1A} receptor 226
5-HT_{1B} receptor 226, 304
5-HT_2 receptor 226
5-HT_2 receptor binding 394
5HT_{2A} 99
5-HT_{2A} receptor 409
5HT_{2C} 99
5-HT_{2C} receptor 342, 409
5-HT_3 receptor 226
Human 179, 217, 335, 342, 379
Human volunteers 272
Hydrocortisone 198
5-Hydroxytryptamine (5HT) 409
Imipramine 114
In vivo microdialysis 153, 299
Incentive-motivation 70
Indian *Ginkgo biloba* (IGb) 148
Inositol phosphate (IP) production 409
Interoceptive stimulus 379
Intravenous 402
Inverse agonist 99
Ischemia 335
Isradipine 335
Kainate 123
Kindling 308
Learning 247
Learning and memory 328
Light/dark test 311
Light-dark transition test 291
Lisuride 409
Locomotion 123
Locomotor activity 34
Lorazepam 357
LS 91
Lysergic acid diethylamide (LSD) 409
Mazindol 44
m-Chlorophenyl-piperazine (mCPP) 291
Memory 8, 349
Meta-analysis 205
Meta-chlorophenylpiperazine (m-CPP) 342
Methadone 217
Methamphetamine 132
3,4-Methylenedioxymethamphetamine (MDMA) 390
Methylphenidate 34
α_1-Microglobulin 374
Milnacipran 190
Modulation 132
Monkey 50
Morphine 15
Mouse 123
Mouse urine 374
MPP^+ 374
MPTP 374
Musical mood induction 272
Nafadotride 284
Neuroendocrine 198
(−)-Nicotine 50
Nicotine 83, 179
Nicotine patch 201
Nicotinic receptor 320
Nisoxetine 44
N,N-Dimethyltryptamine (DMT) 409
Nomifensine 44
Non-contingent 402
Noradrenaline 1, 132, 235, 299
Norepinephrine 8, 190
Nucleus accumbens 153
Obsessive-compulsive disorder 205
Odor 75
Odor detection 75
(±)-7-OH-DPAT 59
8-OH-DPAT 394
Olanzapine 153
Olfaction 75
Olfactory bulbectomy 394
Olfactory sensitivity 75
Operant behaviour 235

Opioids 59
Overnight psychometric performance 172
Oxygen 349
Oxytocin 342
Panic 162
Parabrachial nucleus 304
Parasympathetic nervous system 390
Paraventricular nucleus 304
Passive avoidance 328
Peak procedure 114
Perifornical region of the lateral hypothalamus 105
Pertussis toxin 328
Physostigmine 256
Pigeons 59
(±) Pindolol 226
Plus-maze 311
Positron emission tomography 179, 256
Prefrontal cortex 8, 153
Procaine discrimination 44
Progressive ratio schedule 272
Prolactin 198
Protein kinase A 34
Psychostimulants 24
Quantitative SPECT 335
Quinpirole 75
Rat 70, 83, 114, 148, 247, 272
Rebound anxiety 357
β_1-receptor binding 394
Receptor regulation 99
Regional cerebral blood flow 179
Reinforcement 402
Reinforcer 217
Rhesus monkey 139
Risperidone 367
Runway 247
Satiety 304
SCH 23390 75
Schizophrenia 123, 153
Scopolamine 328
Seizure 308
Self-administration 70, 83, 139, 402
Self-rating 379
Serotonin 190, 198, 304
Serotonin agonist 342
Serotonin receptor 99
Sertindole 367
Signal detection analysis 75
Single photon emission computerized tomography (SPECT) 367
SKF 38393 75
Skin conductance 379
Smoking cessation 201
Sniffing 34
Spiperone 75
Spontaneous behaviour 284
Sprague-Dawley 83
SS 91
SSRI 205
Stereotypy 123
Stimulant 402
Stimulus compounding 70
Stimulus control 70
Stress 24
Striatum 153
Stroke 335
Strychnine 162
Sulpiride 105
Sweet reward 272
Thyrotropin (TSH) 342
Timing 114, 235
Triads 402
Trial 201
Tropanes 139
Tyrosine 1
U99194A 284
Ulinastatin 374
Ultrasound 162, 402
Valsalva maneuver 390
Venlafaxine 190, 394
Ventral tegmental area 105
Vocalization 402
Withdrawal 402
Withdrawal symptom 357
Yoking 83
Zimelidine 114